Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
MRSA spreads through direct contact with another infected person. Most staph infections, including MRSA, initially appear as a bump on the skin that may be red, swollen, painful, warm to the touch, and full of pus or other drainage, and may also be accompanied by a fever. The symptoms of MRSA infections depend strongly on the infection site, the infecting strain, the presence of bacteria virulence factors, the presence of host factors such as comorbidities and immune response, as well as the duration of the infection.
The Methicillin-Resistant Staphylococcus Aureus (MRSA) marketed and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for Methicillin-resistant Staphylococcus aureus (MRSA). Moreover, it analyzes the clinical and commercial landscapes of MRSA, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Key Mechanisms of Action of the MRSA Marketed Drugs
The key mechanisms of action of the MRSA marketed drugs are enzyme inhibitor, protein and peptide inhibitor, cell and cell organelle inhibitor, ligand inhibitor, receptor agonist, receptor antagonist, cell and cell organelle disrupter, and genes, nucleic acids, and related components inhibitor.
MRSA Marketed Drugs Analysis by Mechanisms of Action
For more mechanism of action insights, download a free report sample
Key Routes of Administration in the MRSA Marketed Drugs
The key routes of administration in the MRSA marketed drugs are injections, oral, topical, and inhalational.
MRSA Marketed Drugs Overview by Routes of Administration
For more route of administration insights, download a free report sample
Key Mechanisms of Action of the MRSA Pipeline Drugs Market
The key mechanisms of action of the MRSA pipeline drugs market are enzyme inhibitor, cell and cell organelle disrupter, protein and peptide inhibitor, ligand inhibitor, genes, nucleic acids, and related components inhibitor, cell and cell organelle inhibitor, receptor agonist, toxin inhibitor, and enzyme activator.
MRSA Pipeline Drugs Analysis by Mechanisms of Action
For more mechanism of action insights, download a free report sample
Key Routes of Administration in the MRSA Pipeline Drugs Market
The key routes of administration in the MRSA pipeline drugs market are injections, topical, oral, inhalational, and suppository.
MRSA Pipeline Drugs by Routes of Administration
For more route of administration insights, download a free report sample
Key Molecule Types in the MRSA Pipeline Drugs Market
The key molecule types in the MRSA pipeline drugs market are small molecule, biologic, and oligonucleotide.
MRSA Pipeline Drugs by Molecule Types
For more molecule type insights, download a free report sample
Key Players in the MRSA Marketed and Pipeline Drugs Market
Some of the key players in the MRSA marketed and pipeline drugs market are Allergan, Merck & Co., The Medicines Company, Sanofi, Pfizer, Theravance Biopharma, Kyorin Pharmaceuticals, Melinta Therapeutics, Atox Bio Ltd, and Paratek Pharmaceuticals.
MRSA Marketed and Pipeline Drugs by Players
For more player insights, download a free report sample
MRSA Marketed and Pipeline Drugs Market Report Overview
Key Mechanisms of Action (Marketed Drugs) | Enzyme Inhibitor, Protein and Peptide Inhibitor, Cell and Cell Organelle Inhibitor, Ligand Inhibitor, Receptor Agonist, Receptor Antagonist, Cell and Cell Organelle Disrupter, and Genes, Nucleic Acids, and Related Components Inhibitor |
Key Routes of Administration (Marketed Drugs) | Injections, Oral, Topical, and Inhalational |
Key Mechanisms of Action (Pipeline Drugs) | Enzyme Inhibitor, Cell and Cell Organelle Disrupter, Protein and Peptide Inhibitor, Ligand Inhibitor, Genes, Nucleic Acids, and Related Components Inhibitor, Cell and Cell Organelle Inhibitor, Receptor Agonist, Toxin Inhibitor, and Enzyme Activator |
Key Routes of Administration (Pipeline Drugs) | Injections, Topical, Oral, Inhalational, and Suppository |
Key Molecule Types (Pipeline Drugs) | Small Molecule, Biologic, and Oligonucleotide |
Key Players | Allergan, Merck & Co., The Medicines Company, Sanofi, Pfizer, Theravance Biopharma, Kyorin Pharmaceuticals, Melinta Therapeutics, Atox Bio Ltd, and Paratek Pharmaceuticals |
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, and Route of Administration
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, and Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, and Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the MRSA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MRSA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Merck & Co.
The Medicines Company
Sanofi
Pfizer
Theravance Biopharma
Kyorin Pharmaceuticals
Melinta Therapeutics
Atox Bio Ltd
Paratek Pharmaceuticals
Bayer AG
Nabriva Therapeutics
Motif BioSciences
Melinta Therapeutics
MicuRx Pharmaceuticals
Citius Pharmaceuticals
TaiGen Biotechnology
Basilea Pharmaceuticals
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action of the MRSA marketed drugs?
The key mechanisms of action of the MRSA marketed drugs are enzyme inhibitor, protein and peptide inhibitor, cell and cell organelle inhibitor, ligand inhibitor, receptor agonist, receptor antagonist, cell and cell organelle disrupter, and genes, nucleic acids, and related components inhibitor.
-
What are the key routes of administration in the MRSA marketed drugs?
The key routes of administration in the MRSA marketed drugs are injections, oral, topical, and inhalational.
-
What are the key mechanisms of action of the MRSA pipeline drugs market?
The key mechanisms of action of the MRSA pipeline drugs market are enzyme inhibitor, cell and cell organelle disrupter, protein and peptide inhibitor, ligand inhibitor, genes, nucleic acids, and related components inhibitor, cell and cell organelle inhibitor, receptor agonist, toxin inhibitor, and enzyme activator.
-
What are the key routes of administration in the MRSA pipeline drugs market?
The key routes of administration in the MRSA pipeline drugs market are injections, topical, oral, inhalational, and suppository.
-
What are the key molecule types in the MRSA pipeline drugs market?
The key molecule types in the MRSA pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the key players in the MRSA marketed and pipeline drugs market?
Some of the key players in the MRSA marketed and pipeline drugs market are Allergan, Merck & Co., The Medicines Company, Sanofi, Pfizer, Theravance Biopharma, Kyorin Pharmaceuticals, Melinta Therapeutics, Atox Bio Ltd, and Paratek Pharmaceuticals.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.